 David Binder
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CTLA-4 Antigen | 2 | 2015 | 77 | 0.930 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 195 | 0.910 |
Why?
| | Cancer Vaccines | 3 | 2014 | 138 | 0.840 |
Why?
| | Neoplasms, Experimental | 3 | 2014 | 152 | 0.630 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 5 | 2018 | 44 | 0.600 |
Why?
| | T-Lymphocytes | 4 | 2018 | 1745 | 0.590 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 142 | 0.580 |
Why?
| | Flagellin | 1 | 2017 | 15 | 0.570 |
Why?
| | Immunotherapy | 3 | 2017 | 475 | 0.570 |
Why?
| | Salmonella typhimurium | 1 | 2017 | 158 | 0.510 |
Why?
| | Glioblastoma | 4 | 2018 | 253 | 0.490 |
Why?
| | Cell Cycle Checkpoints | 1 | 2015 | 85 | 0.490 |
Why?
| | Bacterial Vaccines | 1 | 2013 | 61 | 0.430 |
Why?
| | Melanoma, Experimental | 1 | 2013 | 89 | 0.420 |
Why?
| | Melanoma | 2 | 2017 | 629 | 0.410 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 222 | 0.390 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2018 | 114 | 0.390 |
Why?
| | Neoplasms | 3 | 2017 | 2105 | 0.310 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 689 | 0.310 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 342 | 0.270 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 152 | 0.270 |
Why?
| | Immunotherapy, Adoptive | 2 | 2013 | 184 | 0.190 |
Why?
| | Animals | 14 | 2019 | 31762 | 0.190 |
Why?
| | Radiation Tolerance | 2 | 2019 | 92 | 0.190 |
Why?
| | Radioimmunotherapy | 1 | 2019 | 11 | 0.170 |
Why?
| | Lymphocyte Depletion | 1 | 2019 | 116 | 0.170 |
Why?
| | Brain Neoplasms | 2 | 2017 | 984 | 0.160 |
Why?
| | Lymphocyte Activation | 2 | 2013 | 1044 | 0.160 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 26 | 0.160 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 173 | 0.150 |
Why?
| | Radiation, Ionizing | 1 | 2018 | 72 | 0.150 |
Why?
| | Cranial Irradiation | 1 | 2017 | 67 | 0.140 |
Why?
| | Kynurenine | 1 | 2017 | 80 | 0.130 |
Why?
| | Mice | 10 | 2019 | 14916 | 0.130 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 166 | 0.130 |
Why?
| | Tryptophan Oxygenase | 1 | 2015 | 22 | 0.130 |
Why?
| | Gadolinium DTPA | 1 | 2015 | 47 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 436 | 0.120 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 4710 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 751 | 0.120 |
Why?
| | Prostate | 1 | 2015 | 156 | 0.120 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 433 | 0.120 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 283 | 0.120 |
Why?
| | Tumor Escape | 1 | 2013 | 36 | 0.110 |
Why?
| | HLA-A2 Antigen | 1 | 2013 | 36 | 0.110 |
Why?
| | Ovalbumin | 1 | 2013 | 161 | 0.110 |
Why?
| | HLA-D Antigens | 1 | 2013 | 34 | 0.110 |
Why?
| | Contrast Media | 1 | 2015 | 343 | 0.110 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 50 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2013 | 127 | 0.100 |
Why?
| | Antigen Presentation | 1 | 2013 | 189 | 0.100 |
Why?
| | Microvessels | 1 | 2012 | 68 | 0.100 |
Why?
| | Prognosis | 2 | 2017 | 3334 | 0.100 |
Why?
| | Interleukin-15 | 1 | 2012 | 74 | 0.100 |
Why?
| | Macrophages | 2 | 2019 | 1261 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 384 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2018 | 706 | 0.090 |
Why?
| | Epitopes | 1 | 2013 | 435 | 0.090 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 222 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2018 | 2725 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2013 | 668 | 0.080 |
Why?
| | Killer Cells, Natural | 1 | 2012 | 382 | 0.080 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2019 | 195 | 0.080 |
Why?
| | Female | 6 | 2019 | 59507 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2012 | 801 | 0.070 |
Why?
| | Humans | 11 | 2019 | 114757 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 925 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2018 | 2582 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2374 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1122 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2019 | 313 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2018 | 3542 | 0.060 |
Why?
| | Signal Transduction | 1 | 2015 | 4522 | 0.050 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 30 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 66 | 0.040 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2019 | 58 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 153 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 171 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 635 | 0.040 |
Why?
| | Immunomodulation | 1 | 2018 | 84 | 0.040 |
Why?
| | Radiotherapy | 1 | 2018 | 176 | 0.040 |
Why?
| | Drug Synergism | 1 | 2018 | 316 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1151 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2017 | 201 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 339 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1226 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2018 | 787 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 528 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 623 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 815 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2015 | 201 | 0.030 |
Why?
| | Immunity | 1 | 2015 | 121 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1218 | 0.030 |
Why?
| | Catalysis | 1 | 2015 | 292 | 0.030 |
Why?
| | Tryptophan | 1 | 2015 | 135 | 0.030 |
Why?
| | Epithelium | 1 | 2015 | 297 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1176 | 0.030 |
Why?
| | Skin Window Technique | 1 | 2013 | 2 | 0.030 |
Why?
| | Male | 5 | 2018 | 55579 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2013 | 43 | 0.030 |
Why?
| | Aged | 3 | 2017 | 19094 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2013 | 57 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2015 | 398 | 0.030 |
Why?
| | Models, Animal | 1 | 2015 | 345 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2013 | 241 | 0.030 |
Why?
| | Cross-Priming | 1 | 2013 | 19 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1521 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 811 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 347 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 729 | 0.030 |
Why?
| | Tumor Burden | 1 | 2013 | 261 | 0.030 |
Why?
| | Databases, Factual | 1 | 2017 | 1128 | 0.030 |
Why?
| | Microcirculation | 1 | 2012 | 135 | 0.020 |
Why?
| | Inclusion Bodies | 1 | 2012 | 24 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1147 | 0.020 |
Why?
| | Middle Aged | 3 | 2017 | 26757 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2012 | 242 | 0.020 |
Why?
| | Oligopeptides | 1 | 2013 | 234 | 0.020 |
Why?
| | Immunization | 1 | 2013 | 401 | 0.020 |
Why?
| | Adult | 3 | 2017 | 30548 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 936 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2013 | 463 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2557 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 797 | 0.020 |
Why?
| | Biomarkers | 1 | 2018 | 3416 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1086 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1951 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1635 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1314 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 1630 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6350 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1053 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3039 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9089 | 0.010 |
Why?
|
|
Binder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|